Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
AbbVie
Mark C Genovese; Roy Fleischmann; Bernard Combe; Stephen Hall; Andrea Rubbert-Roth; Ying Zhang; Yijie Zhou; Mohamed-Eslam F Mohamed; Sebastian Meerwein; Aileen L Pangan